Apo-Paroxetine Indications/Uses

Depression: APO-PAROXETINE (paroxetine) is indicated for symptomatic relief of depressive illness.
Clinical trials have provided evidence that continuation treatment with paroxetine in patients with moderate to moderately severe depressive disorder is effective for at least 6 months.
Obsessive-Compulsive Disorder: APO-PAROXETINE (paroxetine) is indicated for the symptomatic treatment of obsessive compulsive disorder (OCD). The obsessions or compulsions must be experienced as intrusive, markedly distressing, time-consuming, or interfering significantly with the person's social or occupational functioning.
Panic Disorder: APO-PAROXETINE (paroxetine) is indicated for the symptomatic treatment of panic disorder, with or without agoraphobia.
Social Phobia (Social Anxiety Disorder): APO-PAROXETINE is indicated for the symptomatic relief of generalized social phobia (social anxiety disorder), a disorder characterized by marked and persistent fear, anxious anticipation, or avoidance of multiple social situations (eg. interacting with strangers, attending social gatherings, dealing with authority figures) and/or performance situations (eg. eating, writing, working while being observed, or public speaking). A diagnosis of social phobia/social anxiety disorder should not be made unless the fear, anxious anticipation, or avoidance of social and/or performance situations interferes significantly with the person's normal routine, occupational functioning, or social life, or causes marked distress.
Generalized Anxiety Disorder: APO-PAROXETINE is indicated for the symptomatic relief of anxiety causing significant distress in patients with Generalized Anxiety Disorder (GAD).
Post-traumatic Stress Disorder: APO-PAROXETINE is indicated for the symptomatic treatment of posttraumatic stress disorder (PTSD).
PTSD as defined by DSM-IV requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include re-experiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to clues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger.
A diagnosis of PTSD requires that the symptoms are present for at least one month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.
Long-Term Use of Paroxetine: The effectiveness of paroxetine in long-term use (i.e. more than 8 weeks for GAD and 12 weeks for other indications) has not yet been established in controlled trials for OCD, panic disorder, social phobia (social anxiety disorder), generalized anxiety disorder and posttraumatic stress disorder. Therefore, the physician who elects to use APO-PAROXETINE for extended periods in these indications should periodically re-evaluate the long-term usefulness of the drug for individual patients.